International Urology and Nephrology

, Volume 42, Issue 1, pp 7–12 | Cite as

Long-term outcome of patients with a successful trial without catheter, after treatment with an alpha-adrenergic receptor blocker for acute urinary retention caused by benign prostatic hyperplasia

  • K. L. Lo
  • M. C. K. Chan
  • A. Wong
  • S. M. Hou
  • C. F. Ng
Urology - Original Paper



To perform a retrospective review of long-term outcome for patients with a first episode of acute urinary retention (AUR) who could void successfully after the initial trial without catheter (TWOC) after treatment with an alpha-adrenergic receptor blocker (AR blocker).


The records of 248 patients who presented with a first episode of AUR secondary to benign prostatic hyperplasia (BPH) and who could void successfully after the initial TWOC following treatment with an AR blocker were reviewed during the period January 1998 to December 2001. The characteristics of the patients and the subsequent outcomes were recorded. The primary outcome assessed was failed medical treatment within the five-year follow-up period. Factors correlated with the primary outcome were also assessed.


For these 248 patients, the median follow-up time was 33.0 months (range 0–96 months). The percentage of patients with failed medical treatment at 6, 12, 24, and 60 months was 11.6, 14.3, 28.4, and 50.5%, respectively. Multivariate analysis indicated that only a prostate size >50 ml and serum prostate specific antigen (PSA) level during AUR >10 ng/dl were significant predictors of subsequent requirement for surgical intervention after a successful TWOC.


Although AR blockers increased the success rate of TWOC, approximately half of the patients in this study still required additional intervention within five years. By using appropriate selection criteria, such as a large prostate size (>50 ml) or high serum PSA level during AUR (>10 μg/l), patients who are at greater risk of TWOC failure can be identified, and earlier surgical intervention can be offered to them.


Benign prostate hyperplasia Acute urinary retention Alpha-adrenergic receptor blocker Trial without catheter 


  1. 1.
    Berry SJ, Coffey DS, Walsh PC et al (1984) The development of human benign prostatic hyperplasia with age. J Urol 132(3):474–479PubMedGoogle Scholar
  2. 2.
    Chan PSF, Wong WS, Chan LW et al (1996) Can terazosin (alpha-blocker) relieve acute urinary retention and obviate the need for an indwelling urethral catheter? Br J Urol 77(Suppl 1):7Google Scholar
  3. 3.
    McNeill SA, Hargreave TB, Geffriaud-Ricouard C et al (2001) Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies with alfuzosin. Urology 57(3):459–465CrossRefPubMedGoogle Scholar
  4. 4.
    McNeill SA, Hargreave TB, Roehrborn CG et al (2005) Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. Urology 65(1):83–90CrossRefPubMedGoogle Scholar
  5. 5.
    Palit V, Shah T, Biyani CS et al (2005) Long term follow up of men with Alfuzosin who voided successfully following acute urinary retention. Int Urol Nephrol 37(3):507–510CrossRefPubMedGoogle Scholar
  6. 6.
    Caine M (1986) The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J Urol 136(1):1–4PubMedGoogle Scholar
  7. 7.
    AUA Practice Guidelines Committee (2003) AUA guideline on management of benign prostatic hyperplasia. Chapter 1: Diagnosis and treatment recommendations. J Urol 170(2):530–547CrossRefGoogle Scholar
  8. 8.
    Mebust WK, Holtgrewe HL, Cockett AT et al (1989) Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3, 885 patients. J Urol 141(2):243–247PubMedGoogle Scholar
  9. 9.
    McConnell JD, Roehrborn CG, Bautista OM et al (2003) Medical therapy of prostatic symptoms (MTOPS) research group The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349(25):2387–2398CrossRefPubMedGoogle Scholar
  10. 10.
    Caine M, Pfau A, Perlberg S (1976) The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 48(4):255–263CrossRefPubMedGoogle Scholar
  11. 11.
    McNeill A, Hargreave TB, Members of the ALFAUR study group (2004) Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. J Urol 171(6):2316–2320CrossRefPubMedGoogle Scholar
  12. 12.
    Franciosi M, Koff WJ, Rhoden EL (2007) Correlation between the total volume, transitional zone volume of the prostate, transitional prostate zone index and lower urinary tract symptoms (LUTS). Int Urol Nephrol 39(3):877–971CrossRefGoogle Scholar
  13. 13.
    Roehrborn CG, Malice MP, Cook TJ, Girman CJ (2001) Clinical predictors of spontaneous acute retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 58(2):210–216CrossRefPubMedGoogle Scholar
  14. 14.
    Roehrborn CG for the ALTESS study group (2006) Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute retention: results of a 2-year placebo-controlled study. BJU Int 97(4):734–741CrossRefGoogle Scholar
  15. 15.
    McNeill AS, Rizvi S, Byrne DJ (2004) Prostate size influences the outcome after presenting with acute urinary retention. BJU Int 94(4):559–562CrossRefPubMedGoogle Scholar
  16. 16.
    Roehrborn CG, Bruskewitz R, Nickel GC et al (2000) Urinary retention in patients with BPH treated with Finasteride or Placebo over 4 years. Eur Urol 37(5):528–536CrossRefPubMedGoogle Scholar
  17. 17.
    McNeil SA (2001) Does acute urinary retention respond to alpha-blockers alone? Eur Urol 39(suppl 6):7–12CrossRefGoogle Scholar
  18. 18.
    McConnell JD, Bruskewitz R, Walsh P et al (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group. N Engl J Med 338:557–563CrossRefPubMedGoogle Scholar
  19. 19.
    Debruyne F, Barkin J, van Erps P, Reis M, Tammela TLJ, Roehrborn C (2004) Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 46(4):488–494CrossRefPubMedGoogle Scholar
  20. 20.
    Boyle P, Gould AL, Roehrborn CG (1996) Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 48(3):398–405CrossRefPubMedGoogle Scholar
  21. 21.
    Roehrborn CG, McConnell JD, Lieber M et al (1999) Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and the need for surgery in men with clinical benign prostatic hyperplasia. Urology 53(3):473–480CrossRefPubMedGoogle Scholar
  22. 22.
    Patel AK, Chapple CR (2008) Medical management of lower urinary tract symptoms in men: current treatment and future approaches. Nat Clin Pract Urology 5(4):211–219Google Scholar

Copyright information

© Springer Science+Business Media, B.V. 2009

Authors and Affiliations

  • K. L. Lo
    • 1
  • M. C. K. Chan
    • 1
  • A. Wong
    • 1
  • S. M. Hou
    • 1
  • C. F. Ng
    • 1
  1. 1.Division of Urology, Department of SurgeryThe Chinese University of Hong Kong, Prince of Wales HospitalShatinHong Kong

Personalised recommendations